Viewing Study NCT06171750

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:58 PM
Ignite Modification Date: 2026-02-03 @ 8:09 AM
Study NCT ID: NCT06171750
Status: RECRUITING
Last Update Posted: 2025-07-18
First Post: 2023-11-29
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Sponsor: Ankyra Therapeutics, Inc
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Advanced Solid Tumor View
None Cutaneous Tumor View
None Subcutaneous Tumor View
None Malignant Solid Tumor View
None Solid Tumor View
None Metastatic Solid Tumor View
None Metastasis to Soft Tissue View
None Non Small Cell Lung Cancer View
None Cutaneous Squamous Cell Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None intratumoral View
None intratumoral injection View
None solid tumors View
None superficial tumors View
None nodal tumors View
None subcutaneous tumors View
None visceral tumors View